In November, SAMHSA released results from the 2022 National Survey on Drug Use and Health (NSDUH), an annual, nationally representative survey on mental health, treatment rates, substance use, and more. Among U.S. adults, 23.1% experienced any mental illness (AMI) in...
Engagement and retention of participants in clinical mental illness research studies can be low. To better understand the perspectives of direct stakeholders, researchers surveyed individuals diagnosed with a schizophrenia spectrum condition (SSC) and caregivers of a...
In an innovative justice diversion project, individuals with serious mental illness were tasked with restoring the landscape of community housing as part of their community-based competency restoration. Participants attended educational workshops, received hands-on...
In a unique new study, Boston and Harvard University public health researchers recruited 105 TikTok mental health content creators with diverse professional backgrounds and lived experience to receive evidence-based mental health communication training. Creators...
Research suggests that experiencing substance-induced psychosis increases the risk of developing a schizophrenia spectrum disorder (SSD), but less is known about substance use without psychosis. In a study including 10 million people, Canadian researchers found that...
The U.S. Federal Drug Administration (FDA) has approved the first oral medication, Zurzuvae , for the treatment of postpartum depression (PPD). Onset of PPD can occur during the late stages of pregnancy or after childbirth. Previously, PDD medication was only...
